CART-PSMA-TGFβRDN cell therapy (Tmunity Therapeutics)

N/A

Report date: 2023/10/20 20:06:50

Base Information

Drug NameCART-PSMA-TGFβRDN cell therapy (Tmunity Therapeutics)

Drug Alias NameTmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells therapyDually Armored Chimeric Antigen Receptor (CAR) T Cells (TmPSMA-02) CAR) T cells therapyTmPSMA-02 CAR T Cells therapyTmPSMA-02

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-PSMA

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesTmunity Therapeutics Inc University Of Minnesota University Of Pennsylvania

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Pennsylvania

Inactive CompaniesTceleron Therapeutics Inc

Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A